Actinogen Medical Ltd has released a press release.
ACW completes cognition & depression phase 2 trial enrolment
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- First patient treated in ACW XanaMIA ph 2b Alzheimers trial
- Actinogen HY2024 financial results two key phase 2 trial
- Actinogen HY2024 financial report and Appendix 4D
- Response to ASX Aware Query
- Actinogen awarded UK Innovation Passport for Xanamem
Later from Actinogen Medical
- ACW March 2024 quarterly activity report & Appendix 4C
- Actinogen announces capital raising of up to $8.9 million
- Prospectus - Non-renounceable Entitlement Offer
- Actinogen entitlement offer closed and oversubscribed
- ACW Oversubscribed $3.9 million entitlement offer completed
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical